Scholarlink

Background and aims <p>The impact of clinically significant portal hypertension (CSPH) on patients with hepatocellular carcinoma (HCC) after liver resection remains controversial. This study evaluated the effect of CSPH on postoperative outcomes in very-early, early, and intermediate-stage HCC.</p> Methods <p>In total, 857 patients with HCC undergoing liver resection were identified from a single-institution database. Patients were stratified using the Japan integrated staging (JIS) score, which combines Child–Pugh grade (A: 0, B: 1, C: 2) and TNM stage (I: 0, II: 1, III: 2, IV: 3). Patients were categorized as very-early (JIS 0, <i>n</i> = 198), early (JIS 1, <i>n</i> = 272), and intermediate (JIS 2–4, <i>n</i> = 287). Multivariable Cox regression assessed overall survival (OS).</p> Results <p>Risk-adjusted hazard ratios [95% confidence intervals] for OS in CSPH versus non-CSPH patients were 2.18 [1.14–4.18] (very-early), 0.67 [0.40–1.11] (early), and 1.67 [1.10–2.56] (intermediate). In early stage HCC, CSPH had no significant impact on OS, liver failure (19% vs. 19%, <i>p</i> = 0.925), 90-day mortality (2.6% vs. 2.9%, <i>p</i> = 1.000), or liver decompensation-related death (12% vs. 15%, <i>p</i> = 0.758). However, CSPH patients in very-early and intermediate stages had significantly higher liver failure (0.7% vs. 6.9%, <i>p</i> = 0.027; 6.0% vs. 19%, <i>p</i> = 0.001) and decompensation-related deaths (3.3% vs. 18%, <i>p</i> = 0.027; 9.0% vs. 34%, <i>p</i> &lt; 0.001).</p> Conclusions <p>CSPH’s impact varied by stage. In early stage HCC, CSPH had minimal effect on survival. However, in very-early and intermediate stages, CSPH was associated with worse outcomes. Refining surgical criteria for patients who have HCC with CSPH is essential to balance oncological benefits and hepatic risks.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Stage-specific impact of portal hypertension on outcomes after liver resection in hepatocellular carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月30日

查看全文
  • Yukihiro Watanabe,
  • Masayasu Aikawa,
  • Yoshiki Murase,
  • Kenichiro Takase,
  • Yuichiro Watanabe,
  • Hiroaki Ono,
  • Katsuya Okada,
  • Kojun Okamoto,
  • Isamu Koyama

摘要

Background and aims

The impact of clinically significant portal hypertension (CSPH) on patients with hepatocellular carcinoma (HCC) after liver resection remains controversial. This study evaluated the effect of CSPH on postoperative outcomes in very-early, early, and intermediate-stage HCC.

Methods

In total, 857 patients with HCC undergoing liver resection were identified from a single-institution database. Patients were stratified using the Japan integrated staging (JIS) score, which combines Child–Pugh grade (A: 0, B: 1, C: 2) and TNM stage (I: 0, II: 1, III: 2, IV: 3). Patients were categorized as very-early (JIS 0, n = 198), early (JIS 1, n = 272), and intermediate (JIS 2–4, n = 287). Multivariable Cox regression assessed overall survival (OS).

Results

Risk-adjusted hazard ratios [95% confidence intervals] for OS in CSPH versus non-CSPH patients were 2.18 [1.14–4.18] (very-early), 0.67 [0.40–1.11] (early), and 1.67 [1.10–2.56] (intermediate). In early stage HCC, CSPH had no significant impact on OS, liver failure (19% vs. 19%, p = 0.925), 90-day mortality (2.6% vs. 2.9%, p = 1.000), or liver decompensation-related death (12% vs. 15%, p = 0.758). However, CSPH patients in very-early and intermediate stages had significantly higher liver failure (0.7% vs. 6.9%, p = 0.027; 6.0% vs. 19%, p = 0.001) and decompensation-related deaths (3.3% vs. 18%, p = 0.027; 9.0% vs. 34%, p < 0.001).

Conclusions

CSPH’s impact varied by stage. In early stage HCC, CSPH had minimal effect on survival. However, in very-early and intermediate stages, CSPH was associated with worse outcomes. Refining surgical criteria for patients who have HCC with CSPH is essential to balance oncological benefits and hepatic risks.

Graphical abstract